BMY News and Press, Bristol-Myers Squibb Company

Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial...

2026-03-09 06:44:09 ET The U.S. Food and Drug Administration is reportedly easing some requirements for drugmakers developing copycat versions of costly biologic medications in a bid to bring more competition to the market and lower costs. The agency plans to reduce the need f...

2026-03-08 20:07:46 ET Ever-busy global pharmaceutical company Bristol Myers Squibb (NYSE: BMY) had quite an active February. Since much of the news coming from it was positive, investors were largely bullish on its future, even after price cuts to its No. 1 drug kicked in. This opt...

2026-03-07 08:49:30 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript Bristol-Myers: I'm Buying Post Earnings Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength ...

2026-03-07 07:41:45 ET More on Pfizer, Johnson & Johnson, etc. Pfizer: Obesity Hype And Vaccine Policy Shocks The Sun Will Shine On Moderna Again - Initiating With A Buy Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom J&J subsidi...

Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials Sotyktu is the first and only tyrosine kinase 2 (TYK2) inhibitor to be approved for th...

2026-03-06 10:45:02 ET More on Pfizer, Merck, etc. Pfizer: Obesity Hype And Vaccine Policy Shocks AbbVie: Stabilizes Near $233 While Testing Resistance Pfizer's Portfolio Renewal In Progress - High Yields For The Patient China approves Pfizer’s GLP-1 d...

2026-03-05 15:50:00 ET Considering that most companies don't even stay in business for 20 years, finding stocks worth holding onto for good isn't always easy. Thankfully, some seem to have the qualities that will enable them to perform well for a very long time. Two such companies in th...

2026-03-05 14:03:42 ET A month after the Bureau of Labor Statistics favorably low January Consumer Price Index figures , it will release February’s report on Wednesday, March 11. The upcoming report matters more than ever for two main reasons. First, energy inflation risks ar...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER — Baystreet.ca News Commentary — The global oncology and cancer drugs market, valued at $167 billion in 2023, is projected to reach $335.2 billion by 2033 at a compound annual growth rate of 7.2% [1] . Forecasts...